Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
An update from Immunotech Biopharm Ltd ( (HK:6978) ) is now available.
Immunotech Biopharm Ltd has updated the terms of reference for its remuneration committee, originally established in June 2020, with amendments effective 20 March 2026. The committee is tasked with recommending policies and structures for director and senior management pay, evaluating their performance, overseeing incentive and share schemes, and advising on service contracts and remuneration packages.
The revised framework confirms that the remuneration committee must be composed mainly of independent non-executive directors, with an independent director serving as chairman. It also formalizes meeting procedures, including quorum, notice periods, voting rules, and minute-keeping, reinforcing transparency and governance standards in line with Hong Kong listing requirements.
The most recent analyst rating on (HK:6978) stock is a Hold with a HK$2.50 price target. To see the full list of analyst forecasts on Immunotech Biopharm Ltd stock, see the HK:6978 Stock Forecast page.
More about Immunotech Biopharm Ltd
Immunotech Biopharm Ltd is a Cayman Islands-incorporated company listed on the Hong Kong Stock Exchange under stock code 6978. The company operates in the biopharmaceutical sector, focusing on developing and commercializing innovative therapies, and is subject to Hong Kong listing and corporate governance requirements.
Average Trading Volume: 368,440
Technical Sentiment Signal: Sell
Current Market Cap: HK$1.49B
For an in-depth examination of 6978 stock, go to TipRanks’ Overview page.